The first five participants received a dose on July 27. Citing consumer safety watchdog Rospotrebnadzor, RIA said the next volunteer would be vaccinated on July 30.
Reuters added that a government clinical trial registry shows the institute is evaluating a peptide vaccine based on a platform originally developed for Ebola.
The trial of the Covid-19 vaccine candidate is expected to reach 100 participants between the ages of 18 and 60.
Based on World Health Organization (WHO) records, the Institute of Vector Virology is working on six different potential vaccines against Covid-19.
The country’s first Covid-19 vaccine candidate had already entered the first trials. The candidate is an adenovirus-based vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology.
An early-stage trial was completed this month, and the vaccine is expected to move into full-scale trials next month.
Russia has cleared clinical trials of two formulations of Gamaleya’s Covid-19 vaccine candidate.
An intramuscular solution of the vaccine was tested at the Burdenko Military Hospital while the University of Sechenov evaluated the vaccine as a powder for the preparation of an intramuscular solution.
The data showed the candidate to be safe and elicit an immune response in the participants.
The main objective of the trial was to assess the safety and tolerability of the components of the Covid-19 vaccine in the first group of 18 subjects.
For 28 days after vaccination, participants’ vital signs were within normal limits with no reports of serious adverse events, health problems, complications or adverse effects.